Item 5.02 Departure of Directors or Certain O?cers; Election of Directors;
Appointment of Certain O?cers; Compensatory Arrangements of Certain O?cers.
On June 14, 2022, MediXall Group, Inc. (the "Company") announced the departure
of Neil Swartz as Chairman and CEO of MediXall. Mr. Swartz voluntarily resigned
from his position as Chairman and CEO of MediXall. Mr. Swartz's resignation was
not a result of a disagreement relating to the registrant's operations, policies
or practices. Mr. Swartz had served as Chairman and CEO since its inception.
On June 14, 2022, upon Neil Swart's resignation, the Board of Directors
("Board") announced the appointment of Noel J. Guillama-Alvarez as Chairman of
the Board of Directors and Interim CEO of MediXall Group, Inc. Mr.
Guillama-Alvarez is 62 years old. He is a nationally recognized expert on
healthcare management and operations, as well as the use of technology in
healthcare. Since 1984 he has been Chairman of Guillama, Inc., a strategic
operations management consulting company in healthcare, technology, and a wide
range of projects including medical facilities, commercial complexes and
infrastructure facilities. He holds several patents and is creator of over a
dozen patents currently before the USPTO in a variety of areas. Mr. Guillama is
a co-founder of Quantum Innovations, Inc. and its parent company, The Quantum
Group, Inc., and has been Chief Executive Officer and President since its
inception. Prior to this, Mr. Guillama was the Founder, Chairman, President and
Chief Executive Officer of Metropolitan Health Networks, Inc. (NYSE:MDF) from
its inception in 1996 to 2000 when he left Metropolitan to develop Quantum, a
new breed healthcare company designed to provide multifaceted solutions industry
wide. He is the Past Chair (Currently Director) of the Florida International
University Foundation, a direct support organization of Florida International
University, managing a $230 million endowment. Mr. Guillama is a graduate of
executive and leadership programs at Massachusetts Institute of Technology's,
University of Georgia and Florida International University.
On June 14, 2022, the Company appointed Travis Jackson, Chief Executive Officer
of Health Karma, as a member of the Board of Directors of the Company. Mr.
Jackson was most recently the VP of Strategy & Business Development for Beacon
Health Options from (June 2018-August 2021), one of the largest behavioral
health organizations in the country. Beacon serves more than 40 million
individuals across all 50 states, including nearly 3 million individuals under
comprehensive risk-based behavioral programs. During his tenure as VP, he led
sales, strategy and business development for the company in the West and Midwest
US, with his sales efforts directed towards commercial health insurance plans,
state and county Medicaid plans and large Third Party Administrators. While at
Beacon, the Company was acquired by Anthem in 2020 and currently resides as a
wholly owned subsidiary in Anthem's Diversified Business Group. Prior to Beacon,
Mr. Jackson was Executive VP of Sales for Linkwell Health from (August 2017-
June 2018), where he was responsible for national sales and marketing activities
for the company, with these efforts directed towards health insurance plans,
hospital systems and health services companies. Mr. Jackson also has had success
in his career building new businesses. He was a founder of both Ascendant
Behavioral Health and Highland Springs Specialty Clinics, a series of outpatient
behavioral health clinics. Mr. Jackson was responsible for clinic set up
including locations, billing, hiring and staffing, IT set up and clinic
processes. Prior to that, Mr. Jackson was Founding Partner & Executive Vice
President of Sales of My ePHIT from (2000-2006), where he created a
multimillion-dollar company from an initial idea, through fundraising,
production, active sales and service and renewal phases. During his time, he
participated in the Executive Leadership Team of the company creating, reviewing
and approving all strategy and operations, and was one of the key decision
makers in the sale of the company. At time of sale, My ePHIT had achieved over
23 million paid members.
On June 14, 2022, the Company appointed Michael Swartz, President of MediXall,
as a member of the Board of Directors of the Company. Mr. Swartz is 31 years
old. Since joining MediXall's management team and entering the healthcare
industry in 2016, Michael has led product development projects and has been
directly responsible for bringing the MediXall Healthcare Marketplace to launch.
Previously, Michael was a co-founder and served as a Senior Analyst of Viridian
Capital Advisors from (June 2014- May 2017), where he led all modeling and
valuation work for the firm's M&A and fund-raising assignments. He served as
co-portfolio manager for the Osprey Financial Group from (August 2013-May 2014),
where he analyzed publicly traded companies with market capitalizations from $50
million to $1 billion and prepared buy-side equity reports containing
buy-recommendations and original valuations derived from fundamental & technical
analysis. In addition, Mr. Swartz served as the fund's Asian Economist,
analyzing economic and geopolitical factors and assessing the Asia-Pacific
region for attractive investment opportunities from (August 2013- May 2014).
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements.
Forward-looking statements are based on management's current expectations and
are subject to risks and uncertainties, many of which are beyond the Company's
control, that may cause actual results or events to differ materially from those
projected. These risks and uncertainties include risks described in the section
entitled "Risk Factors" and elsewhere in the Company's Annual Report on Form
10-K filed with the SEC on April 19, 2022 and filings with the SEC, including,
without limitation, its reports on Forms 8-K and 10-Q, and the S-1 registration
filed with the SEC on November 5, 2019, all of which can be obtained on the SEC
website at www.sec.gov. Readers are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date on which they are
made and reflect management's current estimates, projections, expectations and
beliefs. The Company expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in its expectations or any changes in
events, conditions or circumstances on which any such statement is based, except
as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 MediXall Group Inc. Resignation and Appointments Details Letter
104 Cover Page Interactive Data File (the cover page XBRL tags are
embedded within the inline XBRL document)
© Edgar Online, source Glimpses